Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

182.46 -5.79 (-3.08%)
Streaming Delayed Price Updated: 12:40 PM EDT, Aug 17, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 65,140
Open 185.00
Bid (Size) 181.76 (2)
Ask (Size) 182.97 (2)
Prev. Close 188.25
Today's Range 180.67 - 188.84
52wk Range 118.18 - 426.56
Shares Outstanding 1,211,067,023
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher
These monkeypox stocks could be among the best choices to buy in August. Each can make great investments as government responses ramp up. 
Via InvestorPlace
BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care
From BeiGene
Via Business Wire

Performance

YTD
-32.31%
-32.31%
1 Month
+5.63%
+5.63%
3 Month
+31.66%
+31.66%
6 Month
-17.02%
-17.02%
1 Year
-34.97%
-34.97%

More News

Read More
Recap of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Recap: BeiGene Q2 Earnings
Via Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Via Benzinga
BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer
From BeiGene
Via Business Wire
Coinbase, MercadoLibre And Some Other Big Stocks Recording Gains On Thursday
Via Benzinga
BeiGene Reports Second Quarter 2022 Financial Results
From BeiGene, Ltd.
Via Business Wire
Biotech Investors: August's Key PDUFA Catalysts You Must Know
Via Benzinga
Beigene's Inspections Delay Suggest Eventual Approval, Says This Analyst
Via Benzinga
U.S. FDA Defers Decision On BeiGene's Filing For Esophageal Carcinoma Due To Pending Inspection
Via Benzinga
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
Via Benzinga
BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC
From BeiGene
Via Business Wire
BeiGene Appoints Chan Lee as General Counsel
From BeiGene
Via Business Wire
Week In Review: Sequoia China Raises $9 Billion For Healthcare And Technology Investments
Via Talk Markets
BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies
From BeiGene
Via Business Wire
Week In Review: Henlius Signs $196 Million Deal For Two Oncology Bifunctional Sialidase Candidates
Via Talk Markets
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
Via Benzinga
Novartis' Tislelizumab Extends Overall Survival In Late-Stage Esophageal Cancer Study
Via Benzinga
BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma
From BeiGene
Via Business Wire
7 Penny Stocks That Could Triple in 2022
Via InvestorPlace
BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab
From BeiGene
Via Business Wire
SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch
Via Benzinga
BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets
From BeiGene
Via Business Wire
BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatment of CLL/SLL
From BeiGene
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.